Statin use and risk of epilepsy: A nested case-control study

Neurology

Volumn 75, Issue 17, 2010, Pages 1496-1500

  Etminan, Mahyar ^a,b   Samii, Ali ^c   Brophy, James M ^d  

^a VANCOUVER COASTAL HEALTH RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ATORVASTATIN; BENZODIAZEPINE; CERIVASTATIN; FLUINDOSTATIN; MEVINOLIN; NEUROLEPTIC AGENT; PRAVASTATIN; ROSUVASTATIN; SEROTONIN UPTAKE INHIBITOR; SIMVASTATIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; BRAIN TUMOR; CANADA; CARDIAC PATIENT; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; COMORBIDITY; CONTROLLED STUDY; DEMENTIA; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFICACY; DRUG USE; EPILEPSY; FEMALE; HEAD INJURY; HEART INFARCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; REVASCULARIZATION; RISK ASSESSMENT; SENSITIVITY ANALYSIS;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; COHORT STUDIES; COMMUNITY HEALTH PLANNING; CONFIDENCE INTERVALS; EPILEPSY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; PROPENSITY SCORE; QUEBEC; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 78149233435     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181f96253     Document Type: Article

References (22)

1. Brodie MJ, Shorvon SD, Canger R, et al. Commission on European Affairs: appropriate standards of epilepsy care across Europe. Epilepsia 1997;38:1245-1250.
2. Sander JWAS. Some aspects of prognosis in the epilepsies: a review. Epilepsia 1993;34:1007-1016.
3. Smaldone C, Brugaletta S, Pazzano V, et al. Immunomodulator activity of 3-hydroxy-3-methilglutaryl-CoA inhibitors. Cardiovasc Hematol Agents Med Chem 2009;7:279-294.
4. Park E, Velumian AA, Fehlings AG. The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration. J Neurotrauma 2004;21:754-774.
5. Vollmer T, Key L, Durkalski V, et al. Simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004;363:1607-1608.
6. Lee JK, Won JS, Singh AK, et al. Statin inhibits kainic acid-induced seizure and associated inflammation and hippocampal cell death. Neurosci Lett 2008;440:260-264.
7. Pugh MJ, Knoefel JE, Mortensen EM, et al. New-onset epilepsy risk factors in older veterans. J Am Geriatr Soc 2009;57:237-242.
8. Brophy JM, Bourgault C, Brassard P. The use of cholesterol-lowering medications after coronary revascularization. CMAJ 2003;169:1153-1157.
9. Levy AR, Tamblyn RM, Fitchett D, et al. Coding accuracy of hospital discharge data for elderly survivors of myocardial infarction. Can J Cardiol 1999;15:1277-1282.
10. Tamblyn R, Lavoie G, Petrella L, et al. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol 1995;48:999-1009.
11. Jetté N, Reid AY, Quan H, et al. How accurate is ICD coding for epilepsy? Epilepsia 2010;51:62-69.
12. Essebag V, Genest J Jr, Suissa S, et al. The nested case-control study in cardiology. Am Heart J 2003;146:581-590.
13. Nath N, Giri S, Prasad R, et al. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol 2004;174:1273-1286.
14. Pannu R, Christie DK, Barbosa E, et al. Post-trauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury. J Neurochem 2007;101:182-200.
15. Lu D, Goussev A, Chen J, et al. Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury. J Neurotrauma 2004;21:21-32.
16. Piermartiri TC, Vandresen-Filho S, de Araújo Herculano B, et al. Atorvastatin prevents hippocampal cell death due to quinolinic acid-induced seizures in mice by increasing Akt phosphorylation and glutamate uptake. Neurotox Res 2009;16:106-115.
17. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-319.
18. Cleary P, Shorvon S, Tallis R. Late onset seizures as a predictor of subsequent stroke. Lancet 2004;363:1184-1186.
19. Schmidt D, Gram L. Monotherapy versus polytherapy in epilepsy: a reappraisal. CNS Drugs 1995;3:194-208.
20. Brodie MJ, Dichter MA. Antiepileptic drugs. N Engl J Med 1996;334:168-175.
21. Vezzani A, Granata T. Brain inflammation in epilepsy: experimental and clinical evidence. Epilepsia 2005;46:1724-1743.
22. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008;5:167:492-499.